Archeon Medical has raised $9 million (€7.5 million) in Series A funding to expand clinical validation and US commercial activity around EOlife, its ventilation feedback system for manual resuscitation during cardiac arrest. Newfund led the round through its HEKA fund, with participation from funds managed by Eiffel Investment Group and UI Investissement alongside existing investors Majycc Innovation Santé and Karot Capital.
The money is being directed into a programme involving more than 1,500 patients across European and US clinical sites, including Amsterdam UMC, Tualatin Valley Fire & Rescue EMS in Oregon and Rush University Medical Center in Chicago. Results from the Tualatin Valley work are expected in the first quarter of 2027, while the Rush study is scheduled to report in 2029, giving Archeon an evidence programme extending over several years alongside its commercial expansion in the US.
EOlife is used during manual bag ventilation, where the volume of air reaching a patient can vary according to the operator, the airway seal and the rhythm of the resuscitation. A disposable FlowSense sensor sits between the ventilation interface and the self-inflating bag, measuring inspiratory and expiratory airflow so the electronic unit can calculate delivered volume, ventilation frequency and leakage. Those measurements are presented to the rescuer as visual feedback while the rescuer continues to operate the bag and decide how ventilation should be adjusted.
Manual ventilation therefore remains under the control of the responder rather than the EOlife unit, which neither delivers an automated respiratory cycle nor takes over the clinical decision. Its function is to add numerical information to a procedure that otherwise depends heavily on training, observation and feel, giving the person operating the bag an indication of what is happening during each breath. Archeon’s instructions also describe algorithms that filter small airflows generated by chest compressions, reducing the likelihood that movement elsewhere in the resuscitation sequence is interpreted as ventilation.
EOlife is already a regulated commercial device rather than a prototype waiting for market authorisation. In the United States it has been cleared by the FDA as a Class II medical device, while in Europe it is classified as a Class I device under the Medical Device Regulation, allowing Archeon to sell the system while it develops a larger body of clinical evidence. Regulatory clearance establishes the conditions under which the product can be marketed; it does not demonstrate that adding ventilation feedback improves survival, neurological outcome or another clinical endpoint.
Archeon’s earlier French work involved 166 patients experiencing cardiac arrest outside hospital and reported an association between use of EOlife and improved survival with favourable neurological outcomes. Because the study was observational, the result cannot isolate the device as the cause of that difference, particularly when outcomes after cardiac arrest are also affected by response time, chest compression quality, defibrillation, the underlying cause of the arrest and subsequent hospital care. Studies involving a larger patient population and several care settings should provide a broader basis for judging whether the ventilation information changes treatment consistently enough to influence outcomes.
Airflow measurement is only one part of that question, because a device can quantify ventilation accurately without necessarily changing what happens during a resuscitation. The clinical value depends on whether responders interpret the feedback correctly, adjust ventilation when required and continue doing so while chest compressions, defibrillation and other interventions compete for attention. Performance during a controlled training exercise consequently has to translate into behaviour during an emergency, where the operator has considerably less time and attention available.
Wider deployment would bring operational requirements alongside the clinical evidence. Emergency services and hospitals need stocks of disposable sensors, the electronic units have to be checked and maintained, staff require training on the display, and local protocols have to define how the measurements should influence ventilation without distracting from other parts of the resuscitation sequence. Procurement decisions therefore extend beyond the price of the device itself, because each additional component carried on an emergency vehicle or resuscitation trolley creates requirements around consumables, competency, maintenance and governance.
The new studies span services with different operating conditions, which should expose some of those implementation differences rather than examining the technology within one organisation. Prehospital teams work with limited personnel and equipment in uncontrolled environments, while hospital teams may have more clinical resources available but operate within different protocols and decision structures. Evidence collected across both settings can show whether the same measurement system remains useful when the surrounding workflow changes.
Archeon already operates a US subsidiary in New York, employs 25 people and reported $1.5 million of revenue in 2025, placing the Series A after the company has moved beyond the earliest commercial stage. Previous financing included €5.5 million in 2022 and additional funding in 2024, while the latest round is being committed to clinical evidence, US expansion and the organisational work required to support broader adoption rather than to establish whether the underlying hardware can function.
Tualatin Valley is due to report in the first quarter of 2027, with the wider programme continuing through to the Rush study expected in 2029. Results that reproduce the favourable association reported in France would give Archeon a stronger clinical basis for wider use of measured ventilation during cardiac arrest; weaker or mixed findings would be equally important in defining where the additional equipment, training and consumables alter treatment sufficiently to justify their place in routine resuscitation.
